Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23864Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Milionis, H. J. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.date.accessioned | 2015-11-24T19:36:22Z | - |
| dc.date.available | 2015-11-24T19:36:22Z | - |
| dc.identifier.issn | 1522-6417 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23864 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Antihypertensive Agents/*pharmacology | en |
| dc.subject | Blood Pressure/*drug effects | en |
| dc.subject | Endothelin-1/drug effects/metabolism | en |
| dc.subject | Endothelium, Vascular/drug effects/metabolism/physiopathology | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | en |
| dc.subject | Hyperlipidemias/drug therapy/genetics/metabolism/physiopathology | en |
| dc.subject | Hypertension/drug therapy/genetics/metabolism/physiopathology | en |
| dc.subject | Intracellular Signaling Peptides and Proteins/drug effects/metabolism | en |
| dc.subject | Nitric Oxide/biosynthesis | en |
| dc.subject | Protein-Serine-Threonine Kinases/drug effects/metabolism | en |
| dc.subject | Renin-Angiotensin System/drug effects | en |
| dc.subject | rho-Associated Kinases | en |
| dc.title | Analysis of antihypertensive effects of statins | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17519121 | - |
| heal.identifier.secondary | http://www.springerlink.com/content/p476108w2tj28563/fulltext.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | Hypertension and hyperlipidemia, two powerful risk factors of cardiovascular disease (CVD), often coexist. Therefore, treatment should consider the beneficial properties of drugs used to treat either condition. Statins, the mainstay of lipid-lowering therapy, result in a significant clinical benefit both in primary and secondary CVD prevention. In addition to their hypolipidemic capacity, other properties may contribute to statin-induced benefits. Clinical and experimental evidence indicates that statins may modulate blood pressure (BP). The mechanisms by which statins reduce BP seem to be largely independent of their lipid effects. Although small, reductions in BP are possibly clinically relevant. Large landmark studies confirm that statins can reduce CVD risk in hypertensive patients. These findings suggest that statins could be prescribed as an adjunct in treating hypertension with dyslipidemia or even in patients with "normal" cholesterol levels. Whether the effect of statins on BP is accompanied by an additional decrease in clinical outcomes needs to be investigated in long-term, large-scale trials. | en |
| heal.journalName | Curr Hypertens Rep | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Milionis-2007-Analysis of antihype.pdf | 173.01 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
